Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer

• Váldodahkkit: Tian Huan (Dahkki), Bugao Guan (Dahkki), Hongbo Li (Dahkki), Xiu Tu (Dahkki), Chi Zhang (Dahkki), Bin Tang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Monoclonal antibody-based targeted therapies have greatly improved treatment options for patients by binding to the innate immune system. However, the long-term efficacy of such antibodies is limited by mechanisms of drug resistance. Over the last 50 years, with advances in protein engineering techn...